Eli Lilly has agreed to buy biopharmaceutical company Morphic Holding for $3.2 billion in a deal that bolsters the drugmaker’s immunology pipeline.
Eli Lilly has agreed to buy biopharmaceutical company Morphic Holding for $3.2 billion in a deal that bolsters the drugmaker’s immunology pipeline.